Christina S. Chu
Expertise in
16
conditions

Dr. Christina S. Chu

Oncology | Hematology Oncology
2 Cooper Plaza, 
Camden, NJ 
31 Years of Experience
Expertise in
16
conditions
2 Cooper Plaza, 
Camden, NJ 

Overview

Christina Chu is a Hematologist Oncology specialist and an Oncologist in Camden, New Jersey. Dr. Chu has been practicing medicine for over 31 years is highly rated in 16 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy.

Her clinical research consists of co-authoring 57 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Pennsylvania School Of Medicine, 1995

Residency

Hospital of the University of Pennsylvania,Ob/Gyn

Specialties

Oncology
Hematology Oncology

Licenses

Obstetrics & Gynecology in PA

Board Certifications

American Board Of Obstetrics And Gynecology,Gynecologic Oncology , 2006
American Board Of Obstetrics And Gynecology,Obstetrics And Gynecology , 2004

Fellowships

Hospital of the University of Pennsylvania,Gyn. Oncology,2002

Hospital Affiliations

Cooper University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Geisinger
  • HMO
  • POS
  • PPO
Guardian Life Insurance Company
  • MEDICARE PDP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MD Anderson Cancer Center at Cooper - Camden
2 Cooper Plaza, Camden, NJ 08103
Other Locations
Cooper Cancer Center at Medical Commons
225 North Main Street, Cape May Court House, NJ 08210
Cooper Gynecologic Oncology at Medical Commons
223 North Main St, Suite 103, Cape May Court House, NJ 08210
Cooper Gynecologic Oncology at Sewell
2 Plaza Drive, Sewell, NJ 08080
Cooper Specialty Care at Moorestown Campus
400 W Route 38, Suite 100, Moorestown, NJ 08057
Cooper Women's Health at Sewell
4 Plaza Drive, Suite 403, Sewell, NJ 08080
MD Anderson Cancer Center at Cooper - Egg Harbor Township
303 Central Avenue, Suite 4, Egg Harbor Township, NJ 08234

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

57 Total Publications

A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
Journal: Annals of surgery
Published: July 24, 2024
Similar Doctors
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
Expertise in
27
conditions
Dr. Arthur P. Staddon
Hematology Oncology
230 W Washington Sq, 2nd Floor, 
Philadelphia, PA 
 (2.1 miles away)
215-829-6088
Languages Spoken:
English
See accepted insurances

Arthur Staddon is a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Staddon is highly rated in 27 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Alveolar Soft Part Sarcoma, and Bone Tumor.

Expertise in
25
conditions
Dr. Pierluigi Porcu
Oncology
Expertise in
25
conditions
Dr. Pierluigi Porcu
Oncology

Jefferson Medical Oncology-Honickman Center

1101 Chestnut St Fl 14, 
Philadelphia, PA 
 (2.4 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is an Oncologist in Philadelphia, Pennsylvania. Dr. Porcu is highly rated in 25 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology
Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (4.2 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Christina S. Chu

How do I make an appointment with Dr. Christina S. Chu?

You can book an appointment with Dr. Christina S. Chu by calling their office at 855-632-2667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Christina S. Chu a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Christina S. Chu is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Christina S. Chu specialize in?

While Dr. Christina S. Chu is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Christina S. Chu participate in research or clinical trials?

Yes. Dr. Christina S. Chu has published 57 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Christina S. Chu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Christina S. Chu accept my insurance?

Dr. Christina S. Chu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 855-632-2667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chu's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile